/
Our Business We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema ( HAE ) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discover…
Margins and capital returns are both well above average: 38.98% operating margin, ROIC at 198.90%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 94.1% YoY with margins expanding 39.5pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$886M
▲ +94.1% YoY
Net Income (TTM)
-$458M
▲ +396.9% YoY
Op. Margin
-43.11%
▲ +39.5pp YoY
ROIC
-136.51%
▲ +199.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$310M
▲ +749.0% YoY
Op. Cash Flow (TTM)
$313M
▲ +767.8% YoY
Net Debt
$172M
Cash & Equiv.
$238M
5Y CAGR: +117.9%
Continue Research